STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announces the inclusion of the first patient in a clinical Phase 2a study with the lead compound GR3027 in patients with idiopathic hypersomnia.
STOCKHOLM. Umecrine Cognition AB today announces the closing of a financing round raising SEK 20 million (US$2.5 million). Financing will support an exploratory clinical phase IIa trial with the lead compound GR3027 in patients with idiopathic hypersomnia. Current investors Fort Knox Förvaring AB, Stiftelsen Norrlandsfonden, Torbjörn Bäckström, and Karolinska Development (Nasdaq Stockholm: KDEV) participated in the financing round.
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company today announced positive results from its Phase 1b multiple ascending dose trial in healthy male subjects with GR3027, a novel orally active GABAA receptor modulating steroid antagonist, in development for treatment of hepatic encephalopathy (HE) in patients with liver cirrhosis.
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of hepatic encephalopathy (HE) in patients with liver disease, today announces that Dr. Thomas P. Blackburn has been appointed as a new member of its Board of Directors and Senior Development Adviser.
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company whose novel orally-active GABAA receptor modulating steroid, GR3027, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 1 study at The International Liver CongressTM 2017, the annual meeting of the European Association for the Study of the Liver, being held April 19-23, 2017, in Amsterdam, The Netherlands.
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development, today announces the inclusion of the first patient in a clinical Phase 1b/2a study of GR3027, which is in development as a potential new treatment for Hepatic Encephalopathy.